Bentham Science Publishers

Anti-infective agents are a distinct class of pharmacologically important molecules that have served mankind in different capacities to combat life-threatening pathological conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial, and urinary anti-infective agents. However, evolutionary changes, adaptations, and the development of new strains of pathogenic microorganisms have reduced the therapeutic efficacy of existing drugs, thus, limiting their clinical utility over the years.

Frontiers in Anti-Infective Agents Volume 6 is a collection of notable research efforts, successful anti-infective drug development programs, and a comprehensive overview of successful and unsuccessful clinical trials conducted in this domain. This volume continues from the last one with interesting reviews on 1) "Reverse Vaccinology" for vaccination design using computational data to identify vaccine targets, 2) leptospirosis, 3) phage therapy for bacterial infections, 4) quorum sensing inhibitors from natural products, and 5) nitrogen and oxygen-based heterocyclic compounds that can act as anti-infective agents. The volume, therefore, covers a range of frontier topics on anti-infective research and development.

This compilation is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

This eBook series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the eBook series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships.

Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field.

The fourth volume of this series features 5 chapters that cover the following topics:

- An overview of the incidence of neuraminadase resistance in influenza viruses in the Americas from 2004 to 2014

- Phenothiazines and derivative compounds for treating Trypanosoma cruzi infections

- New antibacterial drug targets such as polysaccharide deacetylases

- Improvements in aminoglycoside synthesis and biological activity (including RNA targeting)

- A review of new chemotherapeutic agents against common infections.

This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships.

This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships.

Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field.

The eighth volume of this series features 8 chapters that cover methods for antimicrobial drug discovery (with 2 chapters that focus on genomics) as well as updates on drug development against Helicobacter pylori and emerging coronaviruses, among other interesting topics:

- Eradication of Helicobacter pylori Infection with Non-Bismuth Quadruple Concomitant Therapy

- Drug Discovery Strategies Against Emerging Coronaviruses: A Global Threat

- Opportunities Offered By Fragment-Based Drug Design in Antibiotic Development

- Phage therapy as a Tool for Control of Foodborne Diseases: Advantages and Limitations

- Subtractive Genomics Approaches: Towards Anti-Bacterial Drug Discovery

- Recent Advances in the Discovery of Antimicrobials through Metagenomics

- Phyto-Nano-Antimicrobials: Synthesis, Characterization, Discovery, and Advances

- Aptamers as Anti-infective Agents

21st Century Challenges in Antimicrobial Therapy and Stewardship addresses selected topics that are of importance in the practice of infectious disease management. The text starts by illustrating the global landscape of antimicrobial drug resistance, which influences antimicrobial use and therapeutic decisions in the clinic. The contributors explain the reasons for the spread of antibiotic resistance, the pharmacology of antibiotics of different classes, innovative drug delivery methods which can improve the efficacy and safety of new drug candidates and achieve targeted drug delivery as well as drug resistance monitoring techniques and issues in the practice of antimicrobial stewardship and infection control.

Key Features:

- 14 organized chapters on several aspects of antimicrobial therapy and stewardship

- Introductory knowledge on global antimicrobial trends

- Coverage of molecular basis of antimicrobial resistance in gram positive, gram negative and fungal microbes

- Focused coverage on new developments in antimicrobial drug development, drug delivery, formulation and diagnostic tools

- Information on unmet needs of patients and clinicians, including the treatment of difficult infections

- Comprehensive coverage of issues in antimicrobial stewardship

21st Century Challenges in Antimicrobial Therapy and Stewardship brings to readers – healthcare administrators, educators, pharmacists, clinicians and students, alike – the knowledge of the molecular basis of antimicrobial drug therapy, drug resistance in pathogens and current practices in antimicrobial stewardship programs. This knowledge, in turn, fosters an awareness among healthcare industry participants to collaborate in an interprofessional environment to combat multidrug resistance.

"Frontiers in Anti-Infective Drug Discovery" is an Ebook series devoted to publishing the latest and the most important advances in Anti-Infective drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Infective drug design and discovery. Each volume is devoted to the major advances in Anti-Infective drug design and discovery. The Ebook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

“Frontiers in CNS Drug Discovery” is an eBook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in CNS drug design and discovery. Each volume is devoted to the major advances in CNS drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in CNS Drug Discovery is a book series devoted to publishing reviews which highlight the latest advances in drug design and discovery for disorders of the central nervous system (CNS). Eminent scientists write contributions on all areas of CNS drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series is essential reading for all pharmaceutical scientists involved in CNS drug design and discovery who wish to keep abreast of rapid and important developments in the field.

The third volume of this series brings reviews on brain tumor treatment, neurodegeneration, hyperalgesia, cholinesterase inhibition and much more.

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.